Leukotriene Receptor Antagonist Therapy for the Chemoprevention of Human Rectal Aberrant Crypt Foci: Nonrandomized, Open-Label, Controlled Trial.
Takuma HigurashiKeiichi AshikariShigeki TamuraYusuke SaigusaTomohiro TakatsuNoboru MisawaTsutomu YoshiharaTetsuya MatsuuraAkiko FuyukiHidenori OhkuboTakaomi KessokuKunihiro HosonoMasato YonedaHirokazu TakahashiPublished in: Cancer prevention research (Philadelphia, Pa.) (2022)
We conducted the first LTRA chemoprevention trial for human rectal ACFs, which is considered a surrogate marker of colorectal carcinogenesis. 8-week treatment with LTRA suppressed ACF formation and cell proliferation in colonic epithelium. LTRAs are possible candidates for chemoprevention in colorectal cancer. See related Spotlight, p. 637.